| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Immune-mediated inflammatory disease |
Mar 2024 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Vision threatening non-infectious uveitis |
Mar 2024 |
|
| ADALIMUMAB |
Yuflyma® |
Celltrion Healthcare Australia Pty Ltd |
Complex refractory fistulising Crohn disease Ulcerative colitis Crohn disease Chronic
plaque psoriasis Hidradenitis suppurativa |
Mar 2024 |
|
| AMINO ACID FORMULA SUPPLEMENTED WITH PREBIOTICS, PROBIOTICS AND LONG CHAIN POLYUNSATURATED
FATTY ACIDS |
Neocate® Syneo |
Nutricia Australia Pty Limited |
Cows' milk protein enteropathy Severe cows' milk protein enteropathy with failure
to thrive Combined intolerance to cows' milk protein, soy protein and protein hydrolysate
formulae Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein
and soy protein Cows' milk anaphylaxis Severe intestinal malabsorption including short
bowel syndrome Eosinophilic oesophagitis |
Mar 2024 |
|
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINE |
PKU Lophlex Select LQ |
Nutricia Australia Pty Limited |
Phenylketonuria |
Mar 2024 |
|
| AMINO ACID FORMULA WITH VITAMINS, MINERALS AND LONG CHAIN POLYUNSATURATED FATTY ACIDS
WITHOUT PHENYLALANINE |
PKU Start |
Vitaflo Australia Pty Limited |
Phenylketonuria |
Mar 2024 |
|
| ANIFROLUMAB |
Saphnelo® |
AstraZeneca Pty Ltd |
Systemic lupus erythematosus |
Mar 2024 |
|
| ATEZOLIZUMAB |
Tecentriq® |
Roche Products Pty Ltd |
Locally advanced or metastatic non-small cell lung cancer (NSCLC) Stage IV (metastatic)
NSCLC Extensive-stage small cell lung cancer Advanced (unresectable) Barcelona Clinic
Liver Cancer Stage B or Stage C hepatocellular carcinoma Resected early stage (Stage
II to IIIA) NSCLC |
Mar 2024 |
|
| AVACOPAN |
Tavneos® |
Seqirus (Australia) Pty Ltd |
Granulomatosis with polyangiitis and microscopic polyangiitis |
Mar 2024 |
|
| BECLOMETASONE WITH FORMOTEROL |
Fostair® |
Chiesi Australia Pty Ltd |
Asthma |
Mar 2024 |
|
| BEVACIZUMAB |
Vegzelma® |
Celltrion Healthcare Australia Pty Ltd |
Cancers |
Mar 2024 |
|
| BIMEKIZUMAB |
Bimzelx® |
UCB Australia Proprietary Limited |
Psoriatic arthritis |
Mar 2024 |
|
| BIMEKIZUMAB |
Bimzelx® |
UCB Australia Proprietary Limited |
Non-radial axial spondyloarthritis |
Mar 2024 |
|
| BIMEKIZUMAB |
Bimzelx® |
UCB Australia Proprietary Limited |
Ankylosing spondylitis |
Mar 2024 |
|
| BRENTUXIMAB VEDOTIN |
Adcetris® |
Takeda Pharmaceuticals Australia Pty. Ltd. |
Hodgkin lymphoma |
Mar 2024 |
|
| BUDESONIDE |
Budenofalk® |
Dr Falk Pharma Australia Pty Ltd |
Crohn disease |
Mar 2024 |
|
| BULEVIRTIDE |
Hepcludex® |
Gilead Sciences Pty Limited |
Chronic hepatitis D |
Mar 2024 |
|
| CABOZANTINIB |
Cabometyx® |
Ipsen Pty Ltd |
Advanced clear cell variant renal cell carcinoma in combination with nivolumab |
Mar 2024 |
|
| CABOZANTINIB |
Cabometyx® |
Ipsen Pty Ltd |
Advanced non-clear cell variant renal cell carcinoma |
Mar 2024 |
|
| CABOZANTINIB |
Cabometyx® |
Ipsen Pty Ltd |
Differentiated thyroid cancer (DTC) |
Mar 2024 |
|
| CETUXIMAB |
Erbitux® |
Merck Healthcare Pty Ltd |
Metastatic colorectal cancer |
Mar 2024 |
|
| DABRAFENIB AND TRAMETINIB |
|
Novartis Pharmaceuticals Australia Pty Limited |
Glioma |
Mar 2024 |
|
| DAPAGLIFLOZIN WITH SITAGLIPTIN |
Sidapvia® |
AstraZeneca Pty Ltd |
Type 2 diabetes mellitus |
Mar 2024 |
|
| DUPILUMAB |
Dupixent® |
Sanofi-Aventis Australia Pty Ltd |
Asthma |
Mar 2024 |
|
| EDARAVONE |
Radicava® |
Teva Pharma Australia Pty Ltd |
Amyotrophic lateral sclerosis (ALS) |
Mar 2024 |
|
| ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR |
Trikafta® |
Vertex Pharmaceuticals (Australia) Pty. Ltd. |
Cystic fibrosis |
Mar 2024 |
|
| EMPAGLIFLOZIN |
Jardiance® |
Boehringer Ingelheim Pty Ltd |
Chronic heart failure |
Mar 2024 |
|
| ETRASIMOD |
Velsipity® |
Pfizer Australia Pty Ltd |
Ulcerative colitis |
Mar 2024 |
|
| EVOLOCUMAB |
Repatha® |
Amgen Australia Pty Limited |
Hypercholesterolaemia |
Mar 2024 |
|
| IBRUTINIB |
Imbruvica® |
Janssen-Cilag Pty Ltd |
Chronic lymphocytic leukaemia or Small lymphocytic lymphoma |
Mar 2024 |
|
| ICOSAPENT ETHYL |
Vazkepa® |
Seqirus (Australia) Pty Ltd |
Atherosclerotic cardiovascular disease with elevated triglycerides |
Mar 2024 |
|
| INFLUENZA VACCINE |
Flucelvax® |
Seqirus (Australia) Pty Ltd |
Prevention of influenza |
Mar 2024 |
|
| INFLUENZA VACCINE |
Flublok® |
SANOFI-AVENTIS AUSTRALIA PTY LTD |
Prevention of influenza |
Mar 2024 |
|
| IRINOTECAN |
Onivyde® |
Servier Laboratories (AUST.) Pty. Ltd. |
Pancreatic cancer |
Mar 2024 |
|
| LAROTRECTINIB |
Vitrakvi® |
Bayer Australia Ltd |
Non-small cell lung cancer or soft tissue sarcoma harbouring neurotrophic receptor
tyrosine kinase (NTRK) gene fusions |
Mar 2024 |
|
| LEBRIKIZUMAB |
Ebglyss® |
Eli Lilly Australia Pty Ltd |
Atopic dermatitis |
Mar 2024 |
|
| LEVODOPA WITH CARBIDOPA AND ENTACAPONE |
Lecigon® |
Stada Pharmaceuticals Australia Pty Limited |
Parkinson disease |
Mar 2024 |
|
| MEPOLIZUMAB |
Nucala® |
GlaxoSmithKline Australia Pty Ltd |
Uncontrolled severe asthma |
Mar 2024 |
|
| MIGALASTAT |
Galafold® |
Amicus Therapeutics Pty Ltd |
Fabry disease |
Mar 2024 |
|
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Muscle invasive urothelial carcinoma (MIUC) |
Mar 2024 |
|
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Non-small cell lung cancer |
Mar 2024 |
|
| OFATUMUMAB |
Kesimpta® |
Novartis Pharmaceuticals Australia Pty Limited |
Multiple sclerosis |
Mar 2024 |
|
| OSILODROSTAT |
Isturisa® |
Recordati Rare Diseases Australia Pty. Ltd. |
Cushing syndrome |
Mar 2024 |
|
| PRASUGREL |
Prasugrel SCP |
Generic Health Pty Ltd |
Acute coronary syndrome |
Mar 2024 |
|
| RELUGOLIX WITH ESTRADIOL AND WITH NORETHISTERONE ACETATE |
Ryeqo® |
Gedeon Richter Australia Pty Ltd |
Endometriosis |
Mar 2024 |
|
| RESPIRATORY SYNCYTIAL VIRUS VACCINE |
Abrysvo® |
PFIZER AUSTRALIA PTY LTD |
Lower respiratory tract illness |
Mar 2024 |
|
| RIMEGEPANT |
Nurtec® ODT |
Pfizer Australia Pty Ltd |
Acute migrane attacks |
Mar 2024 |
|
| RISPERIDONE |
Okedi® |
Servier Laboratories (AUST.) Pty. Ltd. |
Schizophrenia |
Mar 2024 |
|
| ROMOSOZUMAB |
Evenity® |
Amgen Australia Pty Limited |
Osteoporosis |
Mar 2024 |
|
| SELUMETINIB |
Koselugo® |
Alexion Pharmaceuticals Australasia Pty Ltd |
Neurofibromatosis type 1 |
Mar 2024 |
|
| SIPONIMOD |
Mayzent® |
Novartis Pharmaceuticals Australia Pty Limited |
Multiple sclerosis |
Mar 2024 |
|
| SODIUM ZIRCONIUM CYCLOSILICATE |
Lokelma® |
AstraZeneca Pty Ltd |
Chronic hyperkalaemia |
Mar 2024 |
|
| TADALAFIL |
Tadalis |
Cipla Australia Pty Ltd |
Pulmonary arterial hypertension |
Mar 2024 |
|
| TALAZOPARIB |
Talzenna® |
Pfizer Australia Pty Ltd |
Prostate cancer |
Mar 2024 |
|
| TIOTROPIUM |
Tiotropium Lupin™ |
Generic Health Pty Ltd |
Chronic obstructive pulmonary disease (COPD) |
Mar 2024 |
|
| TOFACITINIB |
Xeljanz® XR |
Pfizer Australia Pty Ltd |
Rheumatoid arthritis Psoriatic arthritis |
Mar 2024 |
|
| TRASTUZUMAB DERUXTECAN |
Enhertu® |
AstraZeneca Pty Ltd |
Human epidermal growth factor receptor 2 (HER2)-low breast cancer |
Mar 2024 |
|
| USTEKINUMAB |
Stelara® |
Janssen-Cilag Pty Ltd |
Psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis Fistulising
Crohn disease |
Mar 2024 |
|
| USTEKINUMAB |
Wezlana |
Amgen Australia Pty Limited |
Psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis |
Mar 2024 |
|
| VEDOLIZUMAB |
Entyvio® |
Takeda Pharmaceuticals Australia Pty. Ltd. |
Crohn Disease Ulcerative colitis |
Mar 2024 |
|